

产品名称: **SB415286**

产品别名: **SB 415286**

生物活性:																									
Description	SB 415286 is a potent and selective cell permeable inhibitor of GSK-3 α , with an IC ₅₀ of 77.5 nM, and a K _i of 30.75 nM; SB 415286 is equally effective at inhibiting human GSK-3 α and GSK-3 β .																								
IC₅₀ & Target	hGSK-3 α hGSK-3 β																								
	77.5 nM (IC ₅₀) 77.5 nM (IC ₅₀)																								
In Vitro	SB 415286 (SB-415286) inhibits human GSK-3 α with an IC ₅₀ of 77.5 nM, and a K _i of 30.75 nM. SB-415286 stimulates glycogen synthesis in the Chang human liver cell line with EC ₅₀ of 2.9 μ M. SB-415286 stimulates glycogen synthase activity in Chang human liver cells. SB-415286 induces transcription of a β -catenin-LEF/TCF regulated reporter gene in HEK293 cells[1]. SB 415286 (SB-415286, 5-44 μ M) attenuates B65 cell loss mediated by 1 mM H ₂ O ₂ . SB-415286 (5-44 μ M) causes a significant dose-dependent decrease in the fluorescence intensity of DCF, and attenuates B65 ROS production as mediated by 1 mM H ₂ O ₂ . SB-415286 (5-44 μ M) also attenuates ROS production in CGN mediated by 1 mM H ₂ O ₂ [2]. SB-415286 (50 μ M) induces a substantial suppression of immunoprecipitated GSK3 activity by 97%[3].																								
Solvent&Solubility	<i>In Vitro:</i> DMSO : \geq 83.3 mg/mL (231.57 mM) * " \geq " means soluble, but saturation unknown.																								
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing</th> <th>Solvent</th> <th>Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th colspan="2">Concentration</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Stock Solutions</td> <td>1 mM</td> <td></td> <td>2.7799 mL</td> <td>13.8997 mL</td> <td>27.7994 mL</td> </tr> <tr> <td>5 mM</td> <td></td> <td>0.5560 mL</td> <td>2.7799 mL</td> <td>5.5599 mL</td> </tr> <tr> <td>10 mM</td> <td></td> <td>0.2780 mL</td> <td>1.3900 mL</td> <td>2.7799 mL</td> </tr> </tbody> </table>	Preparing	Solvent	Mass	1 mg	5 mg	10 mg	Concentration		Stock Solutions	1 mM		2.7799 mL	13.8997 mL	27.7994 mL	5 mM		0.5560 mL	2.7799 mL	5.5599 mL	10 mM		0.2780 mL	1.3900 mL	2.7799 mL
	Preparing		Solvent	Mass				1 mg	5 mg		10 mg														
		Concentration																							
Stock Solutions	1 mM		2.7799 mL	13.8997 mL	27.7994 mL																				
	5 mM		0.5560 mL	2.7799 mL	5.5599 mL																				
	10 mM		0.2780 mL	1.3900 mL	2.7799 mL																				
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液: 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。																									
References	[1]. Coghlan MP, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000 Oct;7(10):793-803. [2]. Pizarro JG, et al. Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons. Int J Dev Neurosci. 2008 May-Jun;26(3-4):269-76. [3]. MacAulay K, et al. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur J Biochem. 2003 Sep;270(18):3829-38.																								
实验参考:																									
Cell Assay	B65 cells are used after 24 h of in vitro culture. CGN are used after 7-8 days in vitro. Lithium and SB-415286 are dissolved in culture media and DMSO, respectively, and added to the neuronal preparation at the precise concentrations, 1 h before addition H ₂ O ₂ (50 μ M to 1 mM). To assess the loss in cell viability, we use the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium] method. MTT is added to the cells at a final concentration of 250 μ M and incubated for 1 h, allowing the reduction in MTT to produce a dark blue formazan product. Media are then removed, and cells are																								

	<p>dissolved in dimethylsulfoxide. Formazan production is measured by the absorbency change at 595 nm using a microplate reader. Viability results are expressed as percentages. The absorbency measured from non-treated cells is taken to be 100%[2].</p>
Kinase Assay	<p>GSK-3 kinase activity is measured, in the presence or absence of SB-216763 or SB-415286, in a reaction mixture containing final concentrations of: 1 nM human GSK-3α or rabbit GSK3α; 50 mM MOPS pH 7.0; 0.2 mM EDTA; 10 mM Mg-acetate; 7.5 mM β-mercaptoethanol; 5% (w/v) glycerol; 0.01% (w/v) Tween-20; 10% (v/v) DMSO; 28 μM GS-2 peptide substrate. The GS-2 peptide sequence corresponds to a region of glycogen synthase that is phosphorylated by GSK-3. The assay is initiated by the addition of 0.34 μCi [³³P]γ-ATP (IC₅₀ determinations) or 2.7 μCi [³³P]γ-ATP (K_i determinations). The total ATP concentration is 10 μM (IC₅₀ determinations) or ranges from 0 to 45 μM (K_i determinations). Following 30 min incubation at room temperature the assay is stopped by the addition of one third assay volume of 2.5% (v/v) H₃PO₄ containing 21 mM ATP. Samples are spotted onto P30 phosphocellulose mats and these are washed six times in 0.5% (v/v) H₃PO₄. The filter mats are sealed into sample bags containing Wallac betaplate scintillation fluid. ³³P incorporation into the substrate peptide is determined by counting the mats in a Wallac microbeta scintillation counter[1].</p>
References	<p>[1]. Coghlan MP, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. <i>Chem Biol.</i> 2000 Oct;7(10):793-803.</p> <p>[2]. Pizarro JG, et al. Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons. <i>Int J Dev Neurosci.</i> 2008 May-Jun;26(3-4):269-76.</p> <p>[3]. MacAulay K, et al. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. <i>Eur J Biochem.</i> 2003 Sep;270(18):3829-38.</p>

源叶生物